🎉 M&A multiples are live!
Check it out!

Tenaya Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Tenaya Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Tenaya Therapeutics Overview

About Tenaya Therapeutics

Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.


Founded

2016

HQ

United States of America
Employees

97

Financials

LTM Revenue $0.6M

LTM EBITDA -$98.6M

EV

$31.8M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Tenaya Therapeutics Financials

Tenaya Therapeutics has a last 12-month revenue of $0.6M and a last 12-month EBITDA of -$98.6M.

In the most recent fiscal year, Tenaya Therapeutics achieved revenue of n/a and an EBITDA of -$107M.

Tenaya Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Tenaya Therapeutics valuation multiples based on analyst estimates

Tenaya Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$123M -$107M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$124M -$124M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Tenaya Therapeutics Stock Performance

As of April 15, 2025, Tenaya Therapeutics's stock price is $0.

Tenaya Therapeutics has current market cap of $79.7M, and EV of $31.8M.

See Tenaya Therapeutics trading valuation data

Tenaya Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$31.8M $79.7M XXX XXX XXX XXX $-1.14

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Tenaya Therapeutics Valuation Multiples

As of April 15, 2025, Tenaya Therapeutics has market cap of $79.7M and EV of $31.8M.

Tenaya Therapeutics's trades at 51.6x LTM EV/Revenue multiple, and -0.3x LTM EBITDA.

Analysts estimate Tenaya Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Tenaya Therapeutics and 10K+ public comps

Tenaya Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $31.8M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -0.3x XXX XXX XXX
P/E -0.7x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -0.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Tenaya Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Tenaya Therapeutics Valuation Multiples

Tenaya Therapeutics's NTM/LTM revenue growth is 303%

Tenaya Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.2M for the same period.

Over next 12 months, Tenaya Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Tenaya Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Tenaya Therapeutics and other 10K+ public comps

Tenaya Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -12% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.2M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Tenaya Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Genomics & Personalized Medicine comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Tenaya Therapeutics M&A and Investment Activity

Tenaya Therapeutics acquired  XXX companies to date.

Last acquisition by Tenaya Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Tenaya Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Tenaya Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Tenaya Therapeutics

When was Tenaya Therapeutics founded? Tenaya Therapeutics was founded in 2016.
Where is Tenaya Therapeutics headquartered? Tenaya Therapeutics is headquartered in United States of America.
How many employees does Tenaya Therapeutics have? As of today, Tenaya Therapeutics has 97 employees.
Who is the CEO of Tenaya Therapeutics? Tenaya Therapeutics's CEO is Mr. Faraz Ali, M.B.A..
Is Tenaya Therapeutics publicy listed? Yes, Tenaya Therapeutics is a public company listed on NAS.
What is the stock symbol of Tenaya Therapeutics? Tenaya Therapeutics trades under TNYA ticker.
When did Tenaya Therapeutics go public? Tenaya Therapeutics went public in 2021.
Who are competitors of Tenaya Therapeutics? Similar companies to Tenaya Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Tenaya Therapeutics? Tenaya Therapeutics's current market cap is $79.7M
What is the current revenue of Tenaya Therapeutics? Tenaya Therapeutics's last 12-month revenue is $0.6M.
What is the current EBITDA of Tenaya Therapeutics? Tenaya Therapeutics's last 12-month EBITDA is -$98.6M.
What is the current EV/Revenue multiple of Tenaya Therapeutics? Current revenue multiple of Tenaya Therapeutics is 51.6x.
What is the current EV/EBITDA multiple of Tenaya Therapeutics? Current EBITDA multiple of Tenaya Therapeutics is -0.3x.
Is Tenaya Therapeutics profitable? Yes, Tenaya Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.